Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Mishima

Showing results (401-410 of 428) with videos related to

Pageof 43
Sort By:
Kyobu Geka. the Japanese Journal of Thoracic Surgery|March 1, 1984
[A case of WPW syndrome with double accessory conduction pathways (ACPs)]T Imazeki, H Tominaga, H Kaneko, et al.
Kansenshogaku Zasshi. the Journal of the Japanese Association for Infectious Diseases|August 1, 1988
[A case of human fascioliasis diagnosed by serological methods]Y Doutsu, T T Zhang, S Nishihata, et al.
Blood Cancer Journal|September 30, 2017
High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapyY Kusano, M Yokoyama, Y Terui, et al.
Clinical and Experimental Immunology|November 16, 2010
Down-regulation of single immunoglobulin interleukin-1R-related molecule (SIGIRR)/TIR8 expression in intestinal epithelial cells during inflammationC Kadota, S Ishihara, M M Aziz, et al.
Melanoma Research|May 25, 1999
Pharmacokinetics of 10B-p-boronophenylalanine in tumours, skin and blood of melanoma patients: a study of boron neutron capture therapy for malignant melanomaH Fukuda, C Honda, N Wadabayashi, et al.
Molecular Biology of the Cell|February 1, 1992
c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomasY Funasaka, T Boulton, M Cobb, et al.
Clinical and Experimental Immunology|November 17, 2009
A20 is an early responding negative regulator of Toll-like receptor 5 signalling in intestinal epithelial cells during inflammationN Oshima, S Ishihara, M A K Rumi, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|February 1, 1989
In vitro and in vivo studies of boron conjugated melanoma affined biochemicalsB J Allen, J K Brown, M H Mountford, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2009
Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapyM Kodaira, S Takahashi, S Yamada, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 17, 2008
Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapyD Ennishi, M Yokoyama, Y Terui, et al.
Pageof 43

Showing results (401-410 of 428) with videos related to

Sort By:
Pageof 43
Kyobu Geka. the Japanese Journal of Thoracic Surgery|March 1, 1984
[A case of WPW syndrome with double accessory conduction pathways (ACPs)]T Imazeki, H Tominaga, H Kaneko, et al.
Kansenshogaku Zasshi. the Journal of the Japanese Association for Infectious Diseases|August 1, 1988
[A case of human fascioliasis diagnosed by serological methods]Y Doutsu, T T Zhang, S Nishihata, et al.
Blood Cancer Journal|September 30, 2017
High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapyY Kusano, M Yokoyama, Y Terui, et al.
Clinical and Experimental Immunology|November 16, 2010
Down-regulation of single immunoglobulin interleukin-1R-related molecule (SIGIRR)/TIR8 expression in intestinal epithelial cells during inflammationC Kadota, S Ishihara, M M Aziz, et al.
Melanoma Research|May 25, 1999
Pharmacokinetics of 10B-p-boronophenylalanine in tumours, skin and blood of melanoma patients: a study of boron neutron capture therapy for malignant melanomaH Fukuda, C Honda, N Wadabayashi, et al.
Molecular Biology of the Cell|February 1, 1992
c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomasY Funasaka, T Boulton, M Cobb, et al.
Clinical and Experimental Immunology|November 17, 2009
A20 is an early responding negative regulator of Toll-like receptor 5 signalling in intestinal epithelial cells during inflammationN Oshima, S Ishihara, M A K Rumi, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|February 1, 1989
In vitro and in vivo studies of boron conjugated melanoma affined biochemicalsB J Allen, J K Brown, M H Mountford, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2009
Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapyM Kodaira, S Takahashi, S Yamada, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 17, 2008
Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapyD Ennishi, M Yokoyama, Y Terui, et al.
Pageof 43